**Name of journal: World Journal of Meta-Analysis**

**ESPS Manuscript NO: 19343**

**Manuscript Type: EDITORIAL**

**Application of meta-analysis to specific research fields: Lessons learned**

McFarland LV. Impact of the meta-analysis learning curve

**Lynne V McFarland**

**Lynne V McFarland,** Department of Medicinal Chemistry, University of Washington, Seattle, WA 98108-1597, United States

**Lynne V McFarland,** VA Puget Sound Healthcare System, Seattle, WA 98108-1597, United States

**Author contributions**: McFarland LV contributed solely to this work.

**Conflict-of-interest statement:** The author has no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work, not other relationships or activities that could appear to have influenced the submitted work.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:**  **Lynne V McFarland, PhD,** VA Puget Sound Healthcare System, 1660 S. Columbian Way, Seattle, WA 98108-1597, United States. lynne.mcfarland@va.gov

**Telephone:** +1-206-2771780

**Fax:** +1-206-7642935

**Received:** May 5, 2015

**Peer-review started:** May 7, 2015

**First decision:** June 3, 2015

**Revised:** June 15, 2015

**Accepted:** July 7, 2015

**Article in press:**

**Published online:**

**Abstract**

Scientific research is challenged to translate findings from multiple, often conflicting, clinical trials into a simple answer of whether a treatment works or not. The public and healthcare providers alike frequently voice their frustrations when the media reports a treatment working on one day, but seemingly the next day reports a study refuting the previous one. Meta-analyses are being used more commonly by researchers to convey an understandable summary of scientific studies to the general public and healthcare providers. As time goes by, we have learned how to improve meta-analytic techniques to reflect more valid results and when it is appropriate to pool or not to pool results from different studies. Retrospective reviews often don't acknowledge this learning curve and may fail to recommend the most current valid guidelines. This editorial presents an example of how the current use of meta-analysis has shifted in one field (the therapeutic effects of probiotics) and recommendations on how to correctly interpret the results of such an analysis.

**Key words**: Meta-analysis; Study designs; Probiotics; Sensitivity analysis; Meta-regression

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: As meta-analyses are used more frequently and their findings reach a wider scope of people, it is the responsibility of researchers to use current guidelines and appropriately apply their findings to form valid conclusions. As researchers gain experience with this technique, we need to recognize that our methods may change over time. Meta-analysis remains a valuable tool for examining controversies arising from conflicting studies.

McFarland LV. Application of meta-analysis to specific research fields: Lessons learned. *World J Meta-Anal* 2015; In press

**INTRODUCTION**

The lag-time between a scientific discovery and when it is translated into changes in public behavior and beliefs can be protracted. We have never been so challenged in our ability to sort through the onrush of volumes of scientific data to provide timely clinical advice to the public and healthcare providers. The public and healthcare providers face the challenge of obtaining accurate clinical recommendations when the amount of information available is vast and often discordant. In addition, as meta-analyses are used more often, issues in proper application of methods and interpretation of the results need to be re-visited, for example, when it is appropriate to pool studies.

***Public awareness and belief in scientific study results***

We researchers work hard to present new findings for clinical therapies, but how much does the general population really understand? Patients are often confused by information overload and the ambiguity of clinical results, while at the same time suffer from low health literacy[1]. Health literacy measures the ability of the public to understand healthcare providers, as well as reading and comprehending the vast amount of health information. What is alarming is that only 25%-50% of the American and European general populations are scientifically literate, making it difficult for them to decipher complex scientific articles on new medical treatments[2,3]. A global survey across 57 nations found 56% have 'hardly any or only some confidence' in the scientific community[4]. Improving public confidence and awareness of scientific findings is paramount. Science is not a static world. Shifting through studies analyzing similar treatments for the same disease can be frustrating, even for scientists, as newer studies may refute established beliefs and the findings of other studies that seem similar in study design and enrolled participant populations.

Systematic reviews were first developed to provide the public and healthcare providers with a simple summary from multiple studies. The value of systematic reviews is that they allow a detailed examination of many studies, in which researchers try to explain the heterogeneity of the study outcomes, which may to be to a variety of sources ranging from the type of study population, different study designs, differences in study quality and differences in dose and duration of the investigational intervention. But to the disappointment of readers and clinicians, systematic reviews often do not provide a simple answer to the question: “Does this treatment work?”

Meta-analysis was developed to allow combining results from different studies in order to obtain a single pooled estimate of effect or risk from various exposures (behaviors, medications, or interventions) associated with a specific outcome. Meta-analytic analysis involves discerning where heterogeneity exists, identifying the sources from which it may spring and modeling the data to obtain a single pooled estimate of effect. The advantages of meta-analysis include: achieving a higher statistical power due to the greater numbers involved in the pooled population, ability to examine sources of variability over multiple studies while adjusting for common measures shared by studies, and providing one pooled outcome across a variety of studies.

If meta-analysis can provide an answer to 'Does this treatment work?', why is there still confusion in the literature? The problem relates to limitations inherent in the meta-analytic methods and the often too rapid acceptance of conclusions reached by the researchers. If a meta-analysis has pooled dissimilar types of treatments together and the pooled risk estimate shows significant efficacy, people often jump to the conclusion that any of the treatments included in the meta-analysis must be effective. This isn't necessarily so.

Meta-analyses can be misleading if different types of treatments or different types of outcomes are grouped together. The pooled outcomes are also highly dependent upon how the search of the literature is conducted: including or excluding meeting abstracts, non-English trials, years covered, inclusion/exclusion criteria narrow or wide, how incomplete data is handled (exclude or attempt to contact authors of original papers) and different forms of bias (publication bias, study quality, study size). There is a distinct learning curve as both the field of meta-analysis matures and researchers using this technique gain experience.

**THE LEARNING CURVE**

***History***

Meta-analysis developed in the field of astronomy in the 1700s, with the application to the clinical field in 1907[5]. The use of meta-analysis was largely ignored by the clinical field until the 1980s, when the number of publications increased exponentially (Figure 1). Expert panels were convened to reach a consensus on how meta-analysis should be conducted and reported. The guidelines published as PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis, were developed in 1999 and are continually updated, yet the translation of meta-analytic results continues to challenge the general public and scientists alike[6-8].

Meta-analysis is used to assess a wide array of interventions and diseases ranging from the phases of the moon and lunacy[9] to the effects of wine[10,11] and chocolate on cardiovascular disease[12] and the effectiveness of probiotics for many diseases [for example, antibiotic associated diarrhea (AAD), allergies, acute pediatric diarrhea, *etc.*] [13-15].

To demonstrate how we have learned to properly perform and interpret meta-analytic results, let's focus on the field of probiotics for the prevention and treatment of various diseases.

***Examples of inappropriate pooling***

In the early phase of scientific enquiry for a new treatment, there is a tendency to combine different types of interventions or different outcomes to generate a pooled estimate of risk, especially when there is a paucity of available clinical trials published in the literature. This was seen in the field of probiotic randomized clinical trials (RCT).

Some of the earliest meta-analyses of probiotics combined different probiotic strains and species, and reported one pooled estimate of effect. An early meta-analysis done in 2002 assessing probiotics for the prevention of antibiotic-associated diarrhea (AAD) reported a significant protective effect (pooled OR = 0.39, 95%CI: 0.25-0.62) for four RCT of ‘yeast’ probiotics[16]. Fortunately, the only available trials used the same type of yeast (*Saccharomyces boulardii*). However in this same meta-analysis, D'Souza *et al*[16] also concluded that all 'non-yeast' probiotics were effective for AAD, based on a pooled OR from five RCT, which combined the results from four different types of probiotics (*Enterococcus faecium*, *Lactobacillus rhamnosus* GG and three trials with two different mixtures of probiotics). Subsequent meta-analyses did not support the efficacy for three of the types of probiotics and only *L. rhamnosus* GG was found to be effective for AAD in later studies. Another example is from a meta-analysis by Van Niel *et al*[17], who reported a single pooled relative risk estimate (RR) for three different strains and a mixture of two strains of Lactobacilli for the treatment of pediatric diarrhea, and concluded that ‘Lactobacilli was effective for treating pediatric diarrhea’. Again, when these different strains were subsequently analyzed separately, some were effective, but some were not. This meta-analysis did not analyze the different species separately. Another meta-analysis by Deshpande *et al*[18] done in 2010 including 10 different types, either a single strain or mixtures, of probiotics concluded from their pooled RR that a 'combination of Lactobacillus and at least one Bifidobacterium species' was effective for pediatric necrotizing enterocolitis.Unfortunately, there only three of the ten trials used a mixture of Lactobacilli and Bifidobacteria species, but none of the mixtures contained the same strains of bacteria. Even recent publications suffer from inappropriately concluding ‘any of the tested probiotic strains are effective’ once as a significant pooled OR is found. King *et al*[19] pooled the results from 20 RCT using a variety of probiotics (eight RCT using five different Lactobacilli species and 12 trials with different mixtures of probiotic types) and concluded ‘probiotics reduce the duration of respiratory illness’. They did observe significant heterogeneity in the analysis and, although they did sub-group analysis by degree of bias and type of patient population (adult versus pediatric), they failed to do a separate analysis by type of probiotic strain. Khalesi *et al*[20] did a meta-analysis with nine RCT using a variety of different probiotic formulations (four RCT used yogurts, two RCT used milk, one each used capsules, drink or cheese) with nine different probiotic species and concluded ‘consuming probiotics may improve blood pressure’. Although the researchers did do separate analysis by single versus mixtures of probiotics, dose and duration of probiotic treatment and baseline blood pressure, they did not do a separate analysis by the type of probiotic strain. Perhaps the best example of inappropriate use of meta-analysis is seen in the review done by Hempel *et al*[21] published in JAMA in 2012. The authors concluded that ‘the pooled RR from 63 RCT indicated a statistically significant association of probiotic administration with reduction in AAD’. However, eight studies were not on AAD, the pooled studies were a mix of treatment and prevention study designs, and the pooled probiotics included 13 different mixtures and eight different species of single probiotics. The erroneous assumption that once a pooled estimate shows significant efficacy means that any of the treatments included in the analysis are independently effective continues to be a major source of misinterpretation using meta-analysis techniques.

***Solutions for ‘to pool, or not to pool?’***

We have learned over time that the efficacy of probiotics is species and strain specific. Thus, it became apparent that we need to separately analyze different probiotics and not lump them all together. It is now recommended to not pool studies using different probiotic strains and to either exclude non-identical interventions or use separate sub-group analyses for each group with significant heterogeneity or if the disease or intervention is known *a priori* to have different effects[22,23]. Although the use of random-effects models may help to statistically control for some of influences of heterogeneity due to study size or bias, other sources of heterogeneity need to be examined too.

**Limit to one type of intervention:** One of the earliest probiotic meta-analysis limited inclusion to six RCT using the same mixture of probiotics (*Enterococcus faecium* and *Strept. thermophilus*) and found a significant reduction in cholesterol in their pooled outcome measure[24]. As research into probiotics continues, more studies are focusing on including the same type of probiotic strain, allowing them to pool only those probiotics similar in genetic make-up, mechanism-of-action and strain efficacy.

**Sub-group analysis:** Another strategy to examine heterogeneity is sub-group analysis. These sub-groups should be defined a priori in the protocol and several methods may be used, including exclusion sensitivity analysis, stratifying on sub-groups, or use of meta-regression[25,26]. As probiotic meta-analysis research progresses, researchers are separating the analysis by distinct subgroups, including species or strain of probiotic, dose and duration of intervention given, type of enrolled population (adult vs. pediatric) or by study quality. Szajewska *et al*[27] did a meta-analysis of six RCT for the prevention of pediatric AAD, which showed an overall pooled protective RR (RR = 0.44, 95%CI: 0.25-0.77) and used sub-group analysis to show only one strain (*L. rhamnosus* GG) was independently effective. None of the other three types of probiotics had more than one RCT. The scarcity of published articles can limit the applicability of meta-analyses when sub-group analysis by probiotic species results in only one RCT per species. In these cases, we must wait until multiple trials are available before we can use meta-analysis to determine if a particular probiotic strain is effective or not.

Currently, most researchers are now incorporating current guidelines and performing sub-group analysis separately for each type of probiotic and reporting these pooled estimates separately[13,15]. The meta-analysis of Johnston *et al*[28] illustrates what happens when meta-analysis is used when the literature can provide only a limited number of trials for the disease being studied. He included six RCTs, but only two trials used the same type of probiotic (*L. rhamnosus* GG) and although he presented pooled RR for the other trials, this is inappropriate, as there was only one trial each for the other probiotic strains. When I look back at my 2006 meta-analysis of different probiotics for the prevention of AAD, I appropriately reported one pooled RR for six RCT using *S. boulardii* and another pooled RR for the six RCT using *L. rhamnosus* GG[13]. But if I were to report these same results today, I would not have combined the remaining single probiotics and the mixtures in a pooled estimate, rather I would have reported separate estimates of efficacy for each probiotic strain sub-group.

Another consideration is whether to pool the type of disease being treated. One meta-analysis limited inclusion to the same type of probiotic (*S. boulardii*), but included 27 RCT on a variety of diseases, ranging from AAD to traveler's diarrhea[29]. Each type of disease was assessed separately with a systematic review and a meta-analysis was appropriately done only for the disease indication that had sufficient numbers of trials (10 RCT for preventing AAD).

Inflammatory bowel disease encompasses ulcerative colitis, Crohn’s disease and pouchitis, which have different mechanisms and treatment outcomes. In a recent meta-analysis of 23 RCT for IBD, researchers correctly separated the three different disease profiles and additionally did sub-group analyses by the type of probiotic[14]. Only one type of probiotic mixture (VSL#3) was effective for treating both ulcerative colitis and pouchitis, but not for Crohn's disease.

This learning curve for meta-analysis is not limited to just the field of probiotics. A similar learning curve to pool and not pool types of interventions is seen in the progression of studies investigating the role of red versus white wine versus beer for cardiovascular health. An early meta-analysis did not separate the different types of alcohol and pooled results from wine, beer and liquors[10]. A later meta-analysis did separate wine from beer and found a dose-effect on reduced cardiovascular risk from wine, but not beer[30]. Further research determined the main effect on cardiovascular health was due to the resveratrol (from red wine) and later meta-analyses focused on just red wine[11]. Similarly, Hooper *et al*[12] recognized that not all chocolate is alike, as they separated out white versus dark chocolate and cocoa into separate sub-groups in their meta-analysis of chocolate on cardiovascular health.

**CONCLUSION**

Now, we recognize that different types of interventions (for example, different probiotic species or different types of medications) should not be pooled in a meta-analysis, nor should different disease outcomes be pooled. [15,22] Yet, retrospective reviews often fail to acknowledge the learning curve as both the public and scientific researchers learn how best to perform these types of complex analyses. Table 1 shows my recommendations for the proper conduct of meta-analyses. Meta-analysis has its place, but we must resist the urge to jump to an easy conclusion that any of the treatments included in the analysis work once a pooled estimate shows efficacy. Systematic reviews may offer a more transparent analysis of multiple studies for clinicians and the public, but may be more cumbersome to interpret.

**REFERENCES**

1 **Gebele C,** Tscheulin DK, Lindenmeier J, Drevs F, Seemann AK. Applying the concept of consumer confusion to healthcare: development and validation of a patient confusion model. *Health Services Manage Res* 2014; **27**: 10-21 [PMID: 25595013 DOI: 10.1177/0951484814546959]

2 **Shaw TC.** Uncovering health literacy: Developing a remotely administered questionnaire for determining health literacy levels in health disparate populations. *J Hosp Adm* 2014; **3**: 140-156 [PMID: 25126152 DOI: 10.5430/jha.v3n4p149]

3 **Darbyshire JL**, Holman RR, Price HC. Presenting the results of clinical trials to participants. *Clin Med* 2009; **9**: 415-416 [PMID: 19886097 DOI: 10.7861/clinmedicine.9-5-415]

4 **National Data Program for the Sciences (NORC).** 2012 General Social Survey. [accessed 2014 Nov 12]. Available from: URL: http: //www3.norc.org/GSS/

5 **O'Rourke K**. An historical perspective on meta-analysis: dealing quantitatively with varying study results. *J R Soc Med* 2007; **100**: 579-582 [PMID: 18065712 DOI: 10.1258/jrsm.100.12.579]

6 **Moher D**, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. *Lancet* 1999; **354**: 1896-1900 [PMID: 10584742 DOI: 10.1016/S0140-6736(99)04149-5]

7 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009; **62**: e1-34 [PMID: 19631507 DOI: 10.1016/j.jclinepi.2009.06.006]

8 **Moher D**, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; **4**: 1 [PMID: 25554246 DOI: 10.1186/2046-4053-4-1]

9 **Rotton J**, Kelly IW. Much ado about the full moon: a meta-analysis of lunar-lunacy research. *Psychol Bull* 1985; **97**: 286-306 [PMID: 3885282 DOI: 10.1037/0033-2909.97.2.286]

10 **Rimm EB**, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. *BMJ* 1999; **319**: 1523-1528 [PMID: 10591709 DOI: 10.1136/bmj.319.7224.1523]

11 **Sahebkar A**. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev* 2013; **71**: 822-835 [PMID: 24111838 DOI: 10.1111/nure.12081]

12 **Hooper L**, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, Cassidy A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. *Am J Clin Nutr* 2012; **95**: 740-751 [PMID: 22301923 DOI: 10.3945/ajcn.111.023457]

13 **McFarland LV**. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. *Am J Gastroenterol* 2006; **101**: 812-822 [PMID: 16635227 DOI: 10.1111/j.1572-0241.2006.00465.x]

14 **Shen J**, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. *Inflamm Bowel Dis* 2014; **20**: 21-35 [PMID: 24280877 DOI: 10.1097/01.MIB.0000437495.30052.be.]

15 **Szajewska H**. Pooling data on different probiotics is not appropriate to assess the efficacy of probiotics. *Eur J Pediatr* 2014; **173**: 975 [PMID: 24849615 DOI: 10.1007/s00431-014-2340-4]

16 **D'Souza AL,** Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. *BMJ* 2002; **324**: 1361-1369 [PMID:12052801 DOI: 10.1136/bmj.324.7350.1361]

17 **Van Niel CW**, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. *Pediatrics* 2002; **109**: 678-684 [PMID: 11927715 DOI: 10.1542/peds.109.4.678]

18 **Deshpande G**, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. *Pediatrics* 2010; **125**: 921-930 [PMID: 20403939 DOI: 10.1542/peds.2009-1301]

19 **King S**, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. *Br J Nutr* 2014; **112**: 41-54 [PMID: 24780623 DOI: 10.1017/S0007114514000075.]

20 **Khalesi S**, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. *Hypertension* 2014; **64**: 897-903 [PMID: 25047574 DOI: 10.1161/hypertensionaha.03469]

21 **Hempel S**, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA* 2012; **307**: 1959-1969 [PMID: 22570464 DOI: 10.1001/jama.2012.3507]

22 **McFarland LV**. Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections. *Benef Microbes* 2015; **6**: 189-194 [PMID: 24889895 DOI: 10.3920/BM2014.0034]

23 **Guarner F**, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, de Paula JA, Fedorak R, Shanahan F, Sanders ME, Szajewska H, Ramakrishna BS, Karakan T, Kim N. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. *J Clin Gastroenterol* 2012; **46**: 468-481 [PMID: 22688142 DOI: 10.1097/MCG.0b013e3182549092]

24 **Agerholm-Larsen L**, Bell ML, Grunwald GK, Astrup A. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. *Eur J Clin Nutr* 2000; **54**: 856-860 [PMID: 11114681 DOI: 10.1038/sj.ejcn.1601104]

25 **Higgins JPT,** Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011

26 **Sun X**, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. *BMJ* 2010; **340**: c117 [PMID: 20354011 DOI: 10.1136/bmj.c117]

27 **Szajewska H**, Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. *J Pediatr* 2006; **149**: 367-372 [PMID: 16939749 DOI: 10.1016/j.jpeds.2006.04.053]

28 **Johnston BC**, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. *CMAJ* 2006; **175**: 377-383 [PMID: 16908901 DOI: 10.1503/cmaj.051603]

29 **McFarland LV**. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. *World J Gastroenterol* 2010; **16**: 2202-2222 [PMID: 20458757 DOI: 10.3748/wjg.v16.i18.2202]

30 **Di Castelnuovo A**, Rotondo S, Iacoviello L, Donati MB, De Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. *Circulation* 2002; **105**: 2836-2844 [PMID: 12070110 DOI: 10.1161/01.CIR.0000018653.19696.01]

**P-Reviewer:** Bashashati M, Lehert P, Sasaki K **S-Editor:** Tian YL

**L-Editor: E-Editor:**



**Figure 1 Number of publications from PubMed (January 1960-October 2014) citing Meta-analysis by decade. A total of 83786 citations.**

**Table 1** **Recommendations for performing a valid meta-analysis**

|  |
| --- |
| Begin with a systematic review of the literature, carefully reviewing original trial publications |
| Use a standardize data extraction form and independent reviewers to achieve reliable data for the analysis. Use a third reviewer to resolve conflicts |
| Use current guidelines for standardized reporting of meta-analysis results and incorporate a statistician into the analysis team |
| If the exposure/intervention/medication has been shown to have different effects within categories, narrow the groups until similar un-confounded groups are formed (for example, by strain of probiotics not by species or by genus, or by type of drug, not by class) |
| Use caution when using the overall pooled estimate of risk for concluding any type of exposure results in a similar risk of outcome |